Pure ocular mucous membrane pemphigoid reactive with both β4 integrin and the BP180 C-terminal domain.
Pure ocular mucous membrane pemphigoid reactive with both β4 integrin and the BP180 C-terminal domain.
复制标题
纯眼粘膜类天疱疮与 β4 整合素和 BP180 C 末端结构域均具有反应性。
DOI：
10.1111/bjd.13290
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Dauden E.
中科院分区：
文献类型：
--
作者：
Solano-Lopez G;Concha-Garzon MJ;Sanchez-Perez J;Hirako Y;Li X;Ishii N;Hashimoto T;Dauden E.
4 Anforth R，Tembe V，Blumetti T et al.服用BRAF抑制剂的患者皮肤鳞状细胞癌和疣状角化病的突变分析。色素细胞黑素瘤研究2012; 25：569-72。5 Ganzenmueller T，Hage E，Yakushko Y等，在BRAF抑制剂治疗的患者中发生的良性疣状皮肤肿瘤中，通过下一代测序未检测到人病毒序列。Exp Dermatol 2013; 22：725-9. 6 Ko CJ，McNiff JM，Iftner A et al. Vemurafenib（PLX-4032）-induced keratoses：verrucous but not verrucae. J Am Acad Dermatol 2013; 69：e95-6.
4 Anforth R, Tembe V, Blumetti T et al. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012; 25: 569–72. 5 Ganzenmueller T, Hage E, Yakushko Y et al. No human virus sequences detected by next generation sequencing in benign verrucous skin tumors occurring in BRAF inhibitor treated patients. Exp Dermatol 2013; 22: 725–9. 6 Ko CJ, McNiff JM, Iftner A et al. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol 2013; 69: e95–6.